← Human Trials & Peer-Reviewed Studies
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Plain-language guide to NCT07224490: phase 1 interventional trial of Kisspeptin-10, 40 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07224490
- Phase
- phase 1
- Status
- recruiting participants
- Start
- 2026-03-10
- Completion (planned or actual)
- 2030-05
- Participants
- 40 (estimated)
- Design
- na, open label (everyone knows who gets what), other
- Conditions studied
- Reproductive Disorder; Neurodegeneration; SARS-CoV 2; Long COVID
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 1 trial tested Kisspeptin-10.
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome.
The study subjects will receive a single bolus of kisspeptin.
It had 1 arm (groups): Kisspeptin administration (experimental).
Single bolus of kisspeptin.
The registry classes the interventions as drug.
Who Took Part
40 planned participants were the target.
It was open to people of any sex aged from 18 years up to 60 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Female (ages 18-45 years) or Male (ages 18-60 years). For women, negative serum hCG pregnancy test. For cases, diagnosis of post-covid-19 syndrome. For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome.
The full record lists 5 inclusion and 7 exclusion criteria; among the exclusions: active use of illicit drugs (not including marijuana); for women,; trying to become pregnant during protocol participation.
How the Study Was Run
The set-up was single-group and open-label.
Nothing was hidden in this open-label Kisspeptin-10 study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-03-10 with completion listed for 2030-05.
It ran at 1 site in United States.
Its stated primary purpose is other.
What Was Measured
The main thing measured (primary outcome): Difference in mean luteinizing hormone (LH) amplitude between cases and controls (time frame: Day of study visit (one to two hours)).
What This Means in Plain Language
Put simply, this is a phase 1 trial of Kisspeptin-10 in 40 people.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Kisspeptin-10 compound page, all human trials.
Our Notes on the Compound
Kisspeptin-10: A hypothalamic signaling peptide that triggers GnRH, and through it LH and FSH.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.